

Luigi F Meneghini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9354720/publications.pdf>

Version: 2024-02-01

103
papers

2,391
citations

186209

28
h-index

223716

46
g-index

106
all docs

106
docs citations

106
times ranked

1990
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Type 2 Diabetes and HbA1c Predict All-Cause Post-Metabolic and Bariatric Surgery Hospital Readmission. <i>Obesity</i> , 2021, 29, 71-78. | 1.5 | 4 |
| 2 | Optimizing Glucose Meter Downloads at Parkland Diabetes Clinic. <i>Clinical Diabetes</i> , 2021, 39, 199-202. | 1.2 | 1 |
| 3 | Lower-Extremity Amputation Trends Among People With Diabetes in a Large Urban Environment. <i>Diabetes Care</i> , 2021, 44, e91-e92. | 4.3 | 6 |
| 4 | Target attainment in insulin-naïve patients at high risk for hypoglycemia: Results from ACHIEVE Control. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107831. | 1.2 | 3 |
| 5 | Decolonizing Care at Diagnosis: Culture, History, and Family at an Urban Intertribal Clinic. <i>Medical Anthropology Quarterly</i> , 2021, 35, 364-385. | 0.7 | 1 |
| 6 | Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2137-2154. | 2.2 | 47 |
| 7 | Daniel H. Mintz (1930-2020): An Extraordinary Physician-Scientist and a Pioneer in Islet Transplantation. <i>Diabetes Care</i> , 2021, 44, 1727-1733. | 4.3 | 0 |
| 8 | Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. <i>Diabetic Medicine</i> , 2020, 37, 267-276. | 1.2 | 6 |
| 9 | Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. <i>Clinical Diabetes</i> , 2020, 38, 371-381. | 1.2 | 49 |
| 10 | A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2004-2012. | 2.2 | 11 |
| 11 | Physician survey on pre/postprocedure measures for injectable treatments. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 2246-2251. | 0.8 | 1 |
| 12 | Design and Implementation of an Electronic Tool to Measure Medication Adherence at the Point of Care. <i>Clinical Diabetes</i> , 2020, 38, 382-385. | 1.2 | 1 |
| 13 | Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. <i>Diabetes Care</i> , 2020, 43, 2847-2852. | 4.3 | 9 |
| 14 | Cover Image, Volume 22, Issue 11. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, . | 2.2 | 0 |
| 15 | Multilevel Variation in Diabetes Screening Within an Integrated Health System. <i>Diabetes Care</i> , 2020, 43, 1016-1024. | 4.3 | 6 |
| 16 | Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1995-2003. | 2.2 | 10 |
| 17 | Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. <i>Advances in Therapy</i> , 2019, 36, 2310-2326. | 1.3 | 2 |
| 18 | Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 U/mL versus other basal insulin in a real-world setting. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00073. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2133-2141. | 2.2 | 5 |
| 20 | Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study. <i>Diabetes Therapy</i> , 2019, 10, 617-633. | 1.2 | 50 |
| 21 | The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1429-1436. | 2.2 | 28 |
| 22 | Making Inroads in Addressing Population Health in Underserved Communities With Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2019, 32, 303-311. | 0.4 | 5 |
| 23 | Towards a better understanding of postprandial hyperglycemic episodes in people with diabetes: impact on daily functioning. <i>Current Medical Research and Opinion</i> , 2019, 35, 525-533. | 0.9 | 4 |
| 24 | Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 321-329. | 2.2 | 15 |
| 25 | Diabetic Skin Changes Can Benefit from Moisturizer and Cleanser Use: A Review. <i>Journal of Drugs in Dermatology</i> , 2019, 18, 1211-1217. | 0.4 | 4 |
| 26 | Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1298-1301. | 2.2 | 6 |
| 27 | Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1156-1165. | 2.2 | 13 |
| 28 | Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. <i>Diabetes Therapy</i> , 2018, 9, 1347-1358. | 1.2 | 47 |
| 29 | Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 831-839. | 2.2 | 14 |
| 30 | Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. <i>Diabetes Therapy</i> , 2018, 9, 2043-2053. | 1.2 | 6 |
| 31 | More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2314-2318. | 2.2 | 14 |
| 32 | Change in Insulin Dose and HbA1c by Geographical Region—Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study. <i>Diabetes</i> , 2018, 67, 1037-P. | 0.3 | 1 |
| 33 | Implementation of a Perioperative Insulin Protocol in an Advanced Practice Provider (APP)-Led Limb Salvage Hospitalist Team. <i>Diabetes</i> , 2018, 67, . | 0.3 | 0 |
| 34 | Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target—Analyses from the DUAL Program. <i>Diabetes</i> , 2018, 67, . | 0.3 | 0 |
| 35 | Does Improving Glycemic Control Accelerate Healing of Diabetic Foot Ulcers?. <i>Diabetes</i> , 2018, 67, . | 0.3 | 2 |
| 36 | Diabetes Foot Wound Healing—A Collaborative Approach. <i>Diabetes</i> , 2018, 67, 645-P. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Diabetes Inside – Following the Long-Term Impact of a Diabetes Quality Improvement (QI) Initiative in Primary Care. <i>Diabetes</i> , 2018, 67, 7-OR. | 0.3 | 1 |
| 38 | Role of Devices in Insulin Delivery. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 76-78. | 2.4 | 4 |
| 39 | Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1155-1164. | 2.2 | 100 |
| 40 | Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 315-322. | 2.4 | 3 |
| 41 | Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes. <i>Postgraduate Medicine</i> , 2016, 128, 731-739. | 0.9 | 14 |
| 42 | New insulin preparations: A primer for the clinician. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, S27-S33. | 0.6 | 9 |
| 43 | Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 537-544. | 1.7 | 16 |
| 44 | Clinical use of insulin degludec. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 19-31. | 1.1 | 56 |
| 45 | Metabolic Disturbances and the Intestinal Microbiome. <i>US Endocrinology</i> , 2015, 11, 34. | 0.3 | 0 |
| 46 | Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice | 0.8 | 6 |
| 47 | Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths, Misconceptions and Clinical Realities. <i>Patient</i> , 2014, 7, 437-450. | 1.1 | 60 |
| 48 | Stepwise addition of prandial insulin. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 3-4. | 5.5 | 3 |
| 49 | Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences. <i>Endocrine Practice</i> , 2014, 20, 75-83. | 1.1 | 66 |
| 50 | Maximal Sprint Does Not Alter Exercise Hemodynamics or Fuel Use in Individuals with Type-1 Diabetes. <i>Medicine and Science in Sports and Exercise</i> , 2014, 46, 157. | 0.2 | 0 |
| 51 | Maximal Sprints Prevent Hypoglycemia During Exercise and not Recovery in Individuals with Type 1 Diabetes. <i>Medicine and Science in Sports and Exercise</i> , 2014, 46, 546. | 0.2 | 9 |
| 52 | Insulin therapy for type 2 diabetes. <i>Endocrine</i> , 2013, 43, 529-534. | 1.1 | 11 |
| 53 | The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily. <i>Diabetes Care</i> , 2013, 36, 858-864. | 4.3 | 214 |
| 54 | Intensifying Insulin Therapy: What Options Are Available to Patients with Type 2 Diabetes?. <i>American Journal of Medicine</i> , 2013, 126, S28-S37. | 0.6 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Lower Within-Subject Variability in Mean Blood Glucose Concentration with Insulin Degludec vs. Insulin Glargine: A Meta-Analysis of Patients with Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2013, 37, S26. | 0.4 | 0 |
| 56 | Screening, evaluation and management of depression in people with diabetes in primary care. <i>Primary Care Diabetes</i> , 2013, 7, 1-10. | 0.9 | 91 |
| 57 | Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes. <i>Primary Care Diabetes</i> , 2013, 7, 85. | 0.9 | 1 |
| 58 | Reduced Risk of Hypoglycemia with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes and a BMI ≥ 30 kg/m ² : A Meta-analysis of 5 Randomized Trials. <i>Canadian Journal of Diabetes</i> , 2013, 37, S56. | 0.4 | 0 |
| 59 | Insulin degludec improves health-related quality of life (SF-36 [®]) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. <i>Diabetic Medicine</i> , 2013, 30, 226-232. | 1.2 | 32 |
| 60 | Bariatric intervention effective at reversing Type 2 diabetes. <i>Evidence-Based Medicine</i> , 2013, 18, 68-69. | 0.6 | 0 |
| 61 | Reshaping Diabetes Care: The Fundamental Role of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Clinical Practice. <i>Endocrine Practice</i> , 2013, 19, 718-728. | 1.1 | 9 |
| 62 | Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treatment-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 729-736. | 2.2 | 55 |
| 63 | Effect of Baseline Glycosylated Hemoglobin A1C on Glycemic Control and Diabetes Management following Initiation of Once-daily Insulin Detemir in Real-Life Clinical Practice. <i>Endocrine Practice</i> , 2013, 19, 462-470. | 1.1 | 17 |
| 64 | Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 9-14. | 1.2 | 13 |
| 65 | Local Tolerability of Insulin Degludec is Comparable to Insulin Glargine: A Meta-analysis of T1DM and T2DM. <i>Canadian Journal of Diabetes</i> , 2012, 36, S47. | 0.4 | 0 |
| 66 | Less Nocturnal Hypoglycemia for Insulin Degludec vs. Insulin Glargine in Subjects with T1DM and Baseline A1c of 7.5-8.5%: A Meta-Analysis. <i>Canadian Journal of Diabetes</i> , 2012, 36, S46. | 0.4 | 0 |
| 67 | Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 258-267. | 1.7 | 15 |
| 68 | Study of Once Daily Levemir (SOLVE [®]): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 654-661. | 2.2 | 99 |
| 69 | Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. <i>Diabetic Medicine</i> , 2012, 29, 716-720. | 1.2 | 31 |
| 70 | Individualizing insulin therapy. <i>Journal of Family Practice</i> , 2012, 61, S13-27. | 0.2 | 1 |
| 71 | Comparison of 2 Intensification Regimens with Rapid-Acting Insulin Aspart in Type 2 Diabetes Mellitus Inadequately Controlled by Once-Daily Insulin Detemir and Oral Antidiabetes Drugs: The Step-Wise Randomized Study. <i>Endocrine Practice</i> , 2011, 17, 727-736. | 1.1 | 63 |
| 72 | Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. <i>Clinical Immunology</i> , 2011, 139, 290-301. | 1.4 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. <i>Diabetes Care</i> , 2011, 34, 661-665. | 4.3 | 156 |
| 74 | Insulin for intensifying diabetes treatment. <i>Journal of Family Practice</i> , 2011, 60, S21-8. | 0.2 | 0 |
| 75 | Improved Glycemic Control with Insulin Glargine Versus Pioglitazone as Add-On Therapy to Sulfonylurea or Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , 2010, 16, 588-599. | 1.1 | 29 |
| 76 | Practical Aspects and Considerations When Switching Between Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, S-109-S-114. | 2.4 | 11 |
| 77 | Anti-Glycation and Anti-Albuminuric Effects of GLY-230 in Human Diabetes. <i>American Journal of Nephrology</i> , 2010, 31, 110-116. | 1.4 | 17 |
| 78 | Letter to the editor Insulin - Volume 5, Issue 1. <i>Insulin</i> , 2010, 5, 63-65. | 0.2 | 0 |
| 79 | Introduction. <i>Primary Care Diabetes</i> , 2010, 4, S1-S2. | 0.9 | 1 |
| 80 | Insulin detemir: A historical perspective on a modern basal insulin analogue. <i>Primary Care Diabetes</i> , 2010, 4, S31-S42. | 0.9 | 19 |
| 81 | Practical guidance to insulin management. <i>Primary Care Diabetes</i> , 2010, 4, S43-S56. | 0.9 | 14 |
| 82 | A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. <i>European Endocrinology</i> , 2010, 10, 23. | 0.8 | 11 |
| 83 | Early Insulin Treatment in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, S266-S269. | 4.3 | 40 |
| 84 | Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. <i>Advances in Therapy</i> , 2009, 26, 194-207. | 1.3 | 7 |
| 85 | Perioperative management of diabetes: Translating evidence into practice. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S53-S59. | 0.6 | 46 |
| 86 | Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVETM study. <i>International Journal of Clinical Practice</i> , 2008, 62, 659-665. | 0.8 | 65 |
| 87 | Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. <i>International Journal of Clinical Practice</i> , 2008, 62, 1255-1264. | 0.8 | 15 |
| 88 | Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. <i>Current Medical Research and Opinion</i> , 2008, 24, 11-20. | 0.9 | 36 |
| 89 | Clarification of the Similarities and Differences Among Insulin Analog Preparations: Response to Becker. <i>Diabetes Technology and Therapeutics</i> , 2008, 10, 51-53. | 2.4 | 8 |
| 90 | Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 513-529. | 0.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Superior Mesenteric Artery Syndrome in Type 1 Diabetes Masquerading as Gastroparesis. <i>Diabetes Care</i> , 2008, 31, 1983-1984. | 4.3 | 15 |
| 92 | Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. <i>Current Medical Research and Opinion</i> , 2008, 24, 11-20. | 0.9 | 23 |
| 93 | Continued Use of an Integrated Meter with Electronic Logbook Maintains Improvements in Glycemic Control Beyond a Randomized, Controlled Trial. <i>Diabetes Technology and Therapeutics</i> , 2007, 9, 254-264. | 2.4 | 19 |
| 94 | The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE 303 study. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 902-913. | 2.2 | 116 |
| 95 | Why and How to Use Insulin Therapy Earlier in the Management of Type 2 Diabetes. <i>Southern Medical Journal</i> , 2007, 100, 164-174. | 0.3 | 19 |
| 96 | Appropriate advancement of type 2 diabetes therapy. <i>Journal of Family Practice</i> , 2007, 56, 19A-29A; quiz 30A. | 0.2 | 0 |
| 97 | Pharmacotherapies for Diabetes Management: An Update for the Practicing Clinician. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2006, 18, 379-389. | 0.4 | 3 |
| 98 | Prevalence and Associations of Binge Eating Disorder in a Multiethnic Population With Type 2 Diabetes. <i>Diabetes Care</i> , 2006, 29, 2760-2760. | 4.3 | 59 |
| 99 | Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 88-97. | 2.2 | 66 |
| 100 | Evaluation of Metabolic Control Using a Continuous Subcutaneous Glucose Monitoring System in Patients with Type 1 Diabetes Mellitus who Achieved Insulin Independence after Islet Cell Transplantation. <i>Cell Transplantation</i> , 2005, 14, 77-84. | 1.2 | 33 |
| 101 | How Good Is Your Glucose Control?. <i>Diabetes Technology and Therapeutics</i> , 2005, 7, 863-875. | 2.4 | 8 |
| 102 | Obesity, bariatric surgery and type 2 diabetes? a systematic review. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 438-445. | 1.7 | 80 |
| 103 | Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. <i>Clinical Therapeutics</i> , 2004, 26, 379-389. | 1.1 | 35 |